Skip to content

Abstract 15941: Paired Single Cell Transcriptomics Reveals Immune Remodeling During PCSK9 Inhibition in Atherosclerotic Cardiovascular Disease

Nov 2026 · Circulation · 0 citations

Abstract

Background - Proprotein Convertase Subtilisin/Kexin Type 9 inhibitors (PCSK9i) lower LDL-C and reduce ASCVD events, but their effects on circulating immune composition and cell-specific transcriptional programs remain incompletely defined. Hypothesis: PCSK9 inhibition is associated with changes in monocyte transcriptional programs linked to lipid biology and innate immune activation, along with broader changes in PBMC composition and lymphocyte regulatory phenotypes. Methods: In this pilot analysis of an ongoing Mass General Brigham prospective mechanistic study of clinically indicated PCSK9i therapy (NCT05152888), four participants underwent baseline and one-year PBMC single-cell RNA sequencing (scRNA-seq) using the 10x Genomics Chromium platform. One participant was excluded after interval malignancy, leaving three paired participants. Participants were all female, aged 56-73, with baseline LDL-C of 147.67 ± 51.03 mg/dL (Figure 1A). After quality control, Harmony integration, clustering, and manual annotation, paired abundance changes were tested using MASC with participants as a random effect; cell-type differential expression was assessed between baseline and 1 year. Results: PCSK9i therapy reduced LDL-C from 147.7 +/- 51.0 to 98.7+/- 55.4 mg/dl (paired p = 0.01), whereas hsCRP did not change significantly (p = 0.47) (Figure 1A) . We profiled 45,287 PBMCs were profiled and annotated 14 immune populations (Figure 1B). Exploratory abundance modeling showed FDR<0.05 relative enrichment of classical and nonclassical monocytes, CD56 bright and CD56 dim NK cells, Mucosal-Associated Invariant T (MAIT) cells and CD8+ effector cells, with relative reductions in B-cells, total and naïve CD4+ T cells, naïve CD8+ T cells and plasma cells (Figure 1C) . Differential expression was most pronounced in classical monocytes (Figure 2A) , with increased expression of interferon-stimulated and innate immune genes, including GBP1/2/4/5, IFIT1/2/3, ZBP1 and CGAS (Figure 2B-C) . Total and naïve CD4+ T cells showed higher expression of negative regulatory/checkpoint-associated genes (VSIR, UBASH3A, PAG1) and increased expression of cytokine-signaling suppressors (SOCS1, SOCS2) (Fig 2D) . Conclusion: In this paired scRNA-seq pilot study, 1 year of PCSK9 inhibition in ASCVD patients was associated with LDL-C reduction and circulating immune remodeling, including innate immune activation signatures, and CD4+ T cell regulatory transcriptional features. These data support measurable cellular and transcriptional immune changes during PCSK9i therapy but do not establish a clear anti-inflammatory mechanism of CV benefit. Larger paired analyses and functional assays are needed for reproducibility and significance.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.